Januvia Joint Pain Problems Result in FDA Warning for Class of Diabetes Drugs

Federal drug regulators are warning that side effects of Januvia, Onglyza, Nesina and other similar diabetes drugs may cause users to experience severe and debilitating joint pain, which could surface months after they start using the medication.

In a drug safety communication issued on August 28, the FDA indicates that new joint pain warnings will be added to a class of diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

The agency warned that in some cases the pain may be severe enough that it warrants removing individuals from the drug, but cautioned that consumers should not stop taking their diabetes medication without first speaking with their healthcare provider.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

DPP-4 inhibitors currently on the market include Januvia, Onglyza, Nesina and Tradjenta. There are also a number of combination treatments that involve the active ingredient from one of those four drugs, such as Janumet, Kombiglyze, Glyxambi, Jentadueto, Kazano and Oseni.

The medications are widely prescribed to control high blood sugar among adults who have been diagnosed with type 2 diabetes, working by forcing the body to increase the level of hormone insulin produced after eating.

At least 33 cases of severe arthralgia have been linked to DPP-4 use among cases submitted to the FDA Adverse Event Reporting System (FAERS) since October 16, 2006, with the vast majority involving Januvia joint pain problems, as that is the most popular drug in the class.

Most health experts agree that the FAERS database only receives a small fraction of the total number of actual adverse events experienced by patients, with some estimates indicating that there are likely 10 times as many actual events than get reported.

In about two thirds of the reported cases, patients began experiencing symptoms within one month of beginning treatment. However, some cases of joint pain did not begin until 44 days to up to a year after the individual began using the drug.

In most cases, symptoms resolved when the user was taken off of the drug. In some cases, the patients restarted the DPP-4 treatment and the pain did not return.

Consumers are being advised to contact their doctor immediately if they develop severe and persistent joint pain on Januvia, Onglyza, Nesina or other similar diabetes drugs.

Doctors are being warned about the risk of joint pain to make them aware that it could be linked to any DPP-4 inhibitors a patient may be taking. The FDA advises them to consider taking patients who experience such pain off the medication and trying a different diabetes drug.

Januvia (sitagliptin) is Merck & Co.s best-selling drugs and one of the best selling drugs on the market. It brought the company $1.9 billion in sales in just the first half of 2015. Janumet, a combination of Januvia and Metformin, raked in another $1 billion for the company.

In recent years, the drug maker has faced a number of Januvia lawsuits alleging that inadequate warnings were provided about the risk of users developing pancreatic cancer. The cases are consolidated as part of a federal MDL, or multidistrict litigation, before U.S. District Judge Anthony J. Battalglia in the Southern District of California to reduce duplicative discover, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AT&T Data Breach Class Action Claims Telecom Giant
AT&T Data Breach Class Action Claims Telecom Giant "Disregarded" Customer Financial Safety (Posted yesterday)

A Missouri woman is one of the latest person to file an class action claim over the AT&T data breach, after the telecom company admitted that hackers stole millions of customers' personal information and sold it on the internet.

Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL
Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL (Posted 2 days ago)

Plaintiffs say a federal judge should not waste time on a phased discovery plan requiring them to first prove Suboxone strips can cause tooth decay, saying the science is obvious and such a plan could delay resolution of hundreds of product liability lawsuits.